Thibaud Soumagne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thibaud Soumagne has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Degano
University of Grenoble Alpes, INSERM, CHU Grenoble Alpes
12 shared publications Bruno Degano
CRISALIS F-CRIN Network, Toulouse, France; Service Hospitalier Universitaire Pneumologie Physiologie, Pôle Thorax et Vaisseaux, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; Laboratoire HP2, INSERM U1300, Université Grenoble Alpes, Grenoble, France
9 shared publicationsJean-Charles Dalphin
Service de Pneumologie, Oncologie Thoracique et Allergologie Respiratoire, CHRU de Besançon, France
8 shared publications- Jean Charles Dalphin
Service de pneumologie, CHU de Besançon, UMR CNRS 6249 Chrono-environnement, université de Franche-Comté, 3, boulevard Alexandre-Fleming, 25000 Besançon, France
6 shared publications A. Guillien
Service de physiologie-explorations fonctionnelles, Besançon, France
4 shared publicationsAlicia Guillien
Equipe d'Epidémiologie Environnementale, Institute for Advanced Biosciences, Centre de Recherche UGA, INSERM U1209, CNRS UMR 5309, Grenoble, France
4 shared publications
Latest Publications
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Broncho-pneumopathie chronique obstructive secondaire à l’exposition aux poussières organiques : caractérisation pulmonaire et systémique.
La broncho-pneumopathie chronique obstructive (BPCO) est caractérisée par l’existence de symptômes respiratoires et d’une obstruction permanente des voies aériennes. Le tabagisme reste le principal facteur de risque bien que des causes environnementales et professionnelles comme l’exposition aux poussières organiques aient été identifiées.La prévalence de la BPCO secondaire à l’exposition aux poussières organiques est de 8% et est similaire à celle de la BPCO tabagique malgré une prévalence du tabagisme beaucoup plus faible. Les facteurs liés à l’hôte tel que l’atopie semblent être des déterminants de son développement plus que l’importance de l’exposition aux poussières organiques. Par rapport à la BPCO tabagique, la BPCO secondaire aux poussières organiques est caractérisée par une moindre dyspnée d’effort, une meilleure qualité de vie, une capacité de diffusion alvéolo-capillaire moins altérée suggérant une moindre destruction parenchymateuse et une meilleure tolérance à l’exercice. Les comorbidités notamment cardiovasculaires sont moins fréquentes et sont liés au tabagisme plus qu’à l’existence d’une BPCO. L’inflammation systémique est également moins importante avec un profil de type Th2.Un suivi longitudinal de ces patients est actuellement en cours (NCT03468101). Par ailleurs, la prise en charge thérapeutique et le pronostic de cette BPCO reste à déterminer.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Broncho-pneumopathie chronique obstructive secondaire à l’exposition aux poussières organiques : caractérisation pulmonaire et systémique.
La broncho-pneumopathie chronique obstructive (BPCO) est caractérisée par l’existence de symptômes respiratoires et d’une obstruction permanente des voies aériennes. Le tabagisme reste le principal facteur de risque bien que des causes environnementales et professionnelles comme l’exposition aux poussières organiques aient été identifiées.La prévalence de la BPCO secondaire à l’exposition aux poussières organiques est de 8% et est similaire à celle de la BPCO tabagique malgré une prévalence du tabagisme beaucoup plus faible. Les facteurs liés à l’hôte tel que l’atopie semblent être des déterminants de son développement plus que l’importance de l’exposition aux poussières organiques. Par rapport à la BPCO tabagique, la BPCO secondaire aux poussières organiques est caractérisée par une moindre dyspnée d’effort, une meilleure qualité de vie, une capacité de diffusion alvéolo-capillaire moins altérée suggérant une moindre destruction parenchymateuse et une meilleure tolérance à l’exercice. Les comorbidités notamment cardiovasculaires sont moins fréquentes et sont liés au tabagisme plus qu’à l’existence d’une BPCO. L’inflammation systémique est également moins importante avec un profil de type Th2.Un suivi longitudinal de ces patients est actuellement en cours (NCT03468101). Par ailleurs, la prise en charge thérapeutique et le pronostic de cette BPCO reste à déterminer.
- Open Access
- 18 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities
Background: Despite increasing gender parity in medical school enrolment, disparities in career progression and physician well-being persist. This study evaluated professional experiences, health status and perceived gender-related barriers among pulmonologists in France. Methods: A nationwide, anonymous cross-sectional survey (546-item) was distributed to all French pulmonologists between July 2023 and February 2024. Data included work-related health disorders, career paths and gender perceptions. Gender differences in dissatisfaction and health issues were assessed (chi 2 and Fisher's exact tests). Multivariate logistic regression models were used to evaluate the impact of gender on career outcomes. Results: A total of 586 pulmonologists responded (21% response rate), 57% of whom were women; median age of 38 (interquartile range 32–49) years. Job satisfaction was moderate (mean± sd score of 3.5±1.0, out of 5)). Mental health issues were common. 51.5% reported anxiety, 22.0% burnout, 16.9% depression and over 60% had sleep disturbances. Women reported significantly higher rates of anxiety (58.8% versus 44.2%), burnout (27.9% versus 15.4%) and anxiolytic use (23.0% versus 14.5%) than men. Gender was a limiting factor in career choices (OR 1.99, 95% CI 1.41–2.80) and opportunities (OR 2.22, 95% CI 1.57–3.15), particularly among female physicians with children. Women were more likely than men to adjust their career plans for family reasons (18% versus 12%) or job offers (67.0% versus 33.1%). In multivariate analyses, gender remained a limiting factor in career choices (OR 2.00, 95% CI 1.39–2.90) and opportunities (OR 2.39, 95%CI 1.65–3.48), after adjustment for age, number of children and practice settings. Conclusion: This national survey highlights notable gender-based disparities in mental health and career advancement among French pulmonologists.
- 18 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Open AccessFemale pulmonologists experienced poorer health and reduced quality of life related to their professional activities
Background: Despite increasing gender parity in medical school enrolment, disparities in career progression and physician well-being persist. This study evaluated professional experiences, health status and perceived gender-related barriers among pulmonologists in France. Methods: A nationwide, anonymous cross-sectional survey (546-item) was distributed to all French pulmonologists between July 2023 and February 2024. Data included work-related health disorders, career paths and gender perceptions. Gender differences in dissatisfaction and health issues were assessed (chi 2 and Fisher's exact tests). Multivariate logistic regression models were used to evaluate the impact of gender on career outcomes. Results: A total of 586 pulmonologists responded (21% response rate), 57% of whom were women; median age of 38 (interquartile range 32–49) years. Job satisfaction was moderate (mean± sd score of 3.5±1.0, out of 5)). Mental health issues were common. 51.5% reported anxiety, 22.0% burnout, 16.9% depression and over 60% had sleep disturbances. Women reported significantly higher rates of anxiety (58.8% versus 44.2%), burnout (27.9% versus 15.4%) and anxiolytic use (23.0% versus 14.5%) than men. Gender was a limiting factor in career choices (OR 1.99, 95% CI 1.41–2.80) and opportunities (OR 2.22, 95% CI 1.57–3.15), particularly among female physicians with children. Women were more likely than men to adjust their career plans for family reasons (18% versus 12%) or job offers (67.0% versus 33.1%). In multivariate analyses, gender remained a limiting factor in career choices (OR 2.00, 95% CI 1.39–2.90) and opportunities (OR 2.39, 95%CI 1.65–3.48), after adjustment for age, number of children and practice settings. Conclusion: This national survey highlights notable gender-based disparities in mental health and career advancement among French pulmonologists.
- 28 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (8) , 2174-2176
Uncovering treatable traits in severe asthma: The role of cardiopulmonary exercise testing
- 28 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (8) , 2174-2176
Uncovering treatable traits in severe asthma: The role of cardiopulmonary exercise testing
- 29 April 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (8) , 2052-2059.e5
Diagnosis of Dysfunctional Breathing in Severe Asthma
- 29 April 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (8) , 2052-2059.e5
Diagnosis of Dysfunctional Breathing in Severe Asthma
- Open Access
- 16 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (2) , 556
Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. Methods: We conducted a retrospective review of clinical charts from patients with positive cryoglobulin detection at Colmar Hospital between May 2015 and April 2019. Results: Among 166 patients with positive cryoglobulins, the median cryoprecipitate value was 37 mg/L [IQR: 25–70], with 62% of patients below the 50 mg/L threshold. High cryoprecipitate levels were associated with C-virus hepatitis (p = 0.0007), increased fatigue (p = 0.001), fever (p = 0.0013), weight loss (p = 0.028), and musculoskeletal symptoms (p = 0.002). These patients also exhibited decreases in complement fractions (p-values 0.017 to 0.006). At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). Based on the CG type, patients with type I GC had splenomegaly (p = 0.039) and hemopathy (p = 0.001). According to severity at initial presentation, the severe patients had more purpura (p < 0.001), Raynaud’s phenomenon (p = 0.039), and leukocytoclastic vasculitis on skin biopsy (p < 0.001), along with higher cryoprecipitate levels (p = 0.011). Multivariate analysis identified purpura (OR: 10.25), hematological malignancy (OR: 7.06), Raynaud’s phenomenon (OR: 6.41), and cryoprecipitate levels (OR: 1.02) as significant markers of disease severity serving for the development of a severity score for clinical practice. Conclusions: This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis.
- 16 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (2) , 556
Open AccessIdentification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. Methods: We conducted a retrospective review of clinical charts from patients with positive cryoglobulin detection at Colmar Hospital between May 2015 and April 2019. Results: Among 166 patients with positive cryoglobulins, the median cryoprecipitate value was 37 mg/L [IQR: 25–70], with 62% of patients below the 50 mg/L threshold. High cryoprecipitate levels were associated with C-virus hepatitis (p = 0.0007), increased fatigue (p = 0.001), fever (p = 0.0013), weight loss (p = 0.028), and musculoskeletal symptoms (p = 0.002). These patients also exhibited decreases in complement fractions (p-values 0.017 to 0.006). At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). Based on the CG type, patients with type I GC had splenomegaly (p = 0.039) and hemopathy (p = 0.001). According to severity at initial presentation, the severe patients had more purpura (p < 0.001), Raynaud’s phenomenon (p = 0.039), and leukocytoclastic vasculitis on skin biopsy (p < 0.001), along with higher cryoprecipitate levels (p = 0.011). Multivariate analysis identified purpura (OR: 10.25), hematological malignancy (OR: 7.06), Raynaud’s phenomenon (OR: 6.41), and cryoprecipitate levels (OR: 1.02) as significant markers of disease severity serving for the development of a severity score for clinical practice. Conclusions: This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis.
- Open Access
- 28 November 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002620
Factors associated with undiagnosed COPD in patients hospitalised for severe COPD exacerbation
Background: Studies suggest that up to 70% of chronic obstructive pulmonary disease (COPD) cases globally are undiagnosed worldwide. Some of these undiagnosed patients may present with severe exacerbation and factors associated with underdiagnosis in this population are unknown. We investigated the key factors associated with underdiagnosis in two cohorts of patients hospitalised for severe COPD exacerbation at different time points. Methods: This retrospective, multicentre study analysed data from patients hospitalised for COPD exacerbation at two independent centres during two distinct time periods: between 1 January 2017 and 31 December 2018 in the Aquitaine region and between 1 January and 31 December 2022 in Paris. Undiagnosed COPD was defined as the absence of pulmonary function testing before the index exacerbation. Multivariate logistic regression was used to evaluate associations between underdiagnosis and patient characteristics. Results: Among the 424 patients, 93 (21.9%) were undiagnosed before hospitalisation, with a stable rate over time (22% in 2017–2018 and 21% in 2022). Multivariate analysis revealed that underdiagnosis was related to higher forced expiratory volume in one second (FEV1; adjusted OR (aOR)=1.02, p=0.043) and female sex (aOR=1.91, p=0.015). Patients with undiagnosed COPD had significantly lower rehospitalisation and mortality rates. After the initial severe exacerbation, higher mortality was associated with a higher Charlson Comorbidity Index (HR=1.24, p=0.007) and older age (HR=1.05, p=0.008). Conclusion: This retrospective, multicentre study demonstrated that about 20% of patients admitted with severe exacerbation were undiagnosed for COPD. Higher FEV1 and female sex were associated with underdiagnosis, emphasising the need for special attention to this population. These findings highlight the need to improve training and access to spirometry and develop new diagnostic tools that facilitate earlier detection and management of COPD.
- 28 November 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002620
Open AccessFactors associated with undiagnosed COPD in patients hospitalised for severe COPD exacerbation
Background: Studies suggest that up to 70% of chronic obstructive pulmonary disease (COPD) cases globally are undiagnosed worldwide. Some of these undiagnosed patients may present with severe exacerbation and factors associated with underdiagnosis in this population are unknown. We investigated the key factors associated with underdiagnosis in two cohorts of patients hospitalised for severe COPD exacerbation at different time points. Methods: This retrospective, multicentre study analysed data from patients hospitalised for COPD exacerbation at two independent centres during two distinct time periods: between 1 January 2017 and 31 December 2018 in the Aquitaine region and between 1 January and 31 December 2022 in Paris. Undiagnosed COPD was defined as the absence of pulmonary function testing before the index exacerbation. Multivariate logistic regression was used to evaluate associations between underdiagnosis and patient characteristics. Results: Among the 424 patients, 93 (21.9%) were undiagnosed before hospitalisation, with a stable rate over time (22% in 2017–2018 and 21% in 2022). Multivariate analysis revealed that underdiagnosis was related to higher forced expiratory volume in one second (FEV1; adjusted OR (aOR)=1.02, p=0.043) and female sex (aOR=1.91, p=0.015). Patients with undiagnosed COPD had significantly lower rehospitalisation and mortality rates. After the initial severe exacerbation, higher mortality was associated with a higher Charlson Comorbidity Index (HR=1.24, p=0.007) and older age (HR=1.05, p=0.008). Conclusion: This retrospective, multicentre study demonstrated that about 20% of patients admitted with severe exacerbation were undiagnosed for COPD. Higher FEV1 and female sex were associated with underdiagnosis, emphasising the need for special attention to this population. These findings highlight the need to improve training and access to spirometry and develop new diagnostic tools that facilitate earlier detection and management of COPD.
- 8 August 2024
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 86, 101134
Massive hemoptysis: A normal platelet count may not be enough
- 8 August 2024
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 86, 101134
Massive hemoptysis: A normal platelet count may not be enough
- 11 July 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (1) , 2400716
Real world evidence in asthma: what to expect beyond randomised controlled trials?
Shareable abstract Beyond confirming results from RCTs, real world data may help to meet the many challenges yet to be overcome for severe asthmahttps://bit.ly/3waq04R
- 11 July 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (1) , 2400716
Real world evidence in asthma: what to expect beyond randomised controlled trials?
Shareable abstract Beyond confirming results from RCTs, real world data may help to meet the many challenges yet to be overcome for severe asthmahttps://bit.ly/3waq04R
- 15 June 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (12) , 1612-1619
Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy: A Prospective Multi-Centre Agreement Clinical Trial (CAN-ICE)
Rationale: Transbronchial cryobiopsy (TBCB) for the diagnosis of interstitial lung disease (ILD) has shown promising results, but prospective studies with matched surgical lung biopsy (SLB) have yielded conflicting results. Objectives: We aimed to assess within- and between-center diagnostic agreement between TBCB and SLB at both the histopathologic and multidisciplinary discussion (MDD) levels in patients with diffuse ILD. Methods: In a multicenter prospective study, we performed matched TBCB and SLB in patients referred for SLB. After a blinded review by three pulmonary pathologists, all cases were reviewed by three independent ILD teams in an MDD. MDD was performed first with TBCB, then with SLB in a second session. Within-center and between-center diagnostic agreement was evaluated using percentages and correlation coefficients. Measurements and Main Results: Twenty patients were recruited and underwent contemporaneous TBCB and SLB. Within-center diagnostic agreement between TBCB–MDD and SLB–MDD was reached in 37 of the 60 (61.7%) paired observations, resulting in a Cohen’s κ value of 0.46 (95% confidence interval [CI], 0.29–0.63). Diagnostic agreement increased among high-confidence or definitive diagnoses on TBCB–MDD (21 of 29 [72.4%]), but not significantly, and was more likely among cases with SLB–MDD diagnoses of idiopathic pulmonary fibrosis than fibrotic hypersensitivity pneumonitis (13 of 16 [81.2%] vs. 16 of 31 [51.6%]; P = 0.047). Between-center agreement for cases was markedly higher for SLB–MDD (κ = 0.71 [95% CI, 0.52–0.89]) than TBCB–MDD (κ = 0.29 [95% CI, 0.09–0.49]). Conclusions: This study demonstrated moderate TBCB–MDD and SLB–MDD diagnostic agreement for ILD, while between-center agreement was fair for TBCB–MDD and substantial for SLB–MDD. Clinical trial registered with www.clinicaltrials.gov (NCT 02235779).
- 15 June 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (12) , 1612-1619
Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy: A Prospective Multi-Centre Agreement Clinical Trial (CAN-ICE)
Rationale: Transbronchial cryobiopsy (TBCB) for the diagnosis of interstitial lung disease (ILD) has shown promising results, but prospective studies with matched surgical lung biopsy (SLB) have yielded conflicting results. Objectives: We aimed to assess within- and between-center diagnostic agreement between TBCB and SLB at both the histopathologic and multidisciplinary discussion (MDD) levels in patients with diffuse ILD. Methods: In a multicenter prospective study, we performed matched TBCB and SLB in patients referred for SLB. After a blinded review by three pulmonary pathologists, all cases were reviewed by three independent ILD teams in an MDD. MDD was performed first with TBCB, then with SLB in a second session. Within-center and between-center diagnostic agreement was evaluated using percentages and correlation coefficients. Measurements and Main Results: Twenty patients were recruited and underwent contemporaneous TBCB and SLB. Within-center diagnostic agreement between TBCB–MDD and SLB–MDD was reached in 37 of the 60 (61.7%) paired observations, resulting in a Cohen’s κ value of 0.46 (95% confidence interval [CI], 0.29–0.63). Diagnostic agreement increased among high-confidence or definitive diagnoses on TBCB–MDD (21 of 29 [72.4%]), but not significantly, and was more likely among cases with SLB–MDD diagnoses of idiopathic pulmonary fibrosis than fibrotic hypersensitivity pneumonitis (13 of 16 [81.2%] vs. 16 of 31 [51.6%]; P = 0.047). Between-center agreement for cases was markedly higher for SLB–MDD (κ = 0.71 [95% CI, 0.52–0.89]) than TBCB–MDD (κ = 0.29 [95% CI, 0.09–0.49]). Conclusions: This study demonstrated moderate TBCB–MDD and SLB–MDD diagnostic agreement for ILD, while between-center agreement was fair for TBCB–MDD and substantial for SLB–MDD. Clinical trial registered with www.clinicaltrials.gov (NCT 02235779).
- Open Access
- 14 March 2023
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 19 (1) , 220260
Impact of triple therapy on mortality in COPD
Only a few therapies have been shown to prolong survival in specific patients with COPD. In recent years, the IMPACT and the ETHOS trials suggested that triple therapy (a combination of inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) given in a single inhaler) may reduce mortality compared with dual bronchodilation.These results need however to be interpreted with caution. These trials were not powered by design to evaluate the impact of triple therapy on mortality as mortality was a secondary outcome. In addition, mortality reduction has to be put in perspective with the low mortality rate in both studies (<2%). Furthermore, a key methodological issue is that up to 70–80% of patients had ICS withdrawal at the enrolment in the LABA/LAMA arms, but none in the ICS-containing treatment arms. It is possible that ICS withdrawal may have contributed to some early death events. Finally, the inclusion and exclusion criteria of both trials were designed to select patients likely to respond to ICS.There are no conclusive data yet that triple therapy reduces mortality in COPD. Future, well-designed and -powered trials are needed to validate the findings on mortality.
- 14 March 2023
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 19 (1) , 220260
Open AccessImpact of triple therapy on mortality in COPD
Only a few therapies have been shown to prolong survival in specific patients with COPD. In recent years, the IMPACT and the ETHOS trials suggested that triple therapy (a combination of inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) given in a single inhaler) may reduce mortality compared with dual bronchodilation.These results need however to be interpreted with caution. These trials were not powered by design to evaluate the impact of triple therapy on mortality as mortality was a secondary outcome. In addition, mortality reduction has to be put in perspective with the low mortality rate in both studies (<2%). Furthermore, a key methodological issue is that up to 70–80% of patients had ICS withdrawal at the enrolment in the LABA/LAMA arms, but none in the ICS-containing treatment arms. It is possible that ICS withdrawal may have contributed to some early death events. Finally, the inclusion and exclusion criteria of both trials were designed to select patients likely to respond to ICS.There are no conclusive data yet that triple therapy reduces mortality in COPD. Future, well-designed and -powered trials are needed to validate the findings on mortality.